NCT00915525View on ClinicalTrials.gov

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

PHASE3CompletedINTERVENTIONAL
Enrollment

829

Participants

Timeline

Start Date

February 1, 2010

Primary Completion Date

August 5, 2014

Study Completion Date

August 5, 2014

Conditions
Overactive BladderUrinary Incontinence
Interventions
BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.

Trial Locations (8)

Unknown

Newport Beach

Ghent

Victoria

Prague

Tübingen

Warsaw

Moscow

London

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00915525 - Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence | Biotech Hunter | Biotech Hunter